Acacia Pharma is preparing for filing an NDA for BAREMSIS™ for the treatments of post operative nausea & vomiting.
Amplyx Pharmaceutical’s is developing a new class of antifungal medicine to overcome the limitations of existing therapeutic options. Amplyx is developing APX001, a broad-spectrum antifungal drug with a novel mechanism of action for the treatment of life-threatening invasive fungal infections caused by resistant Candida and by rare, hard-to-treat molds. Intravenous and oral formulations of APX001 have been evaluated in a Phase 1 clinical program, with Phase 2 clinical trials in invasive aspergillosis and invasive candidiasis planned for initiation in early 2018.
Atox Bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. Initial focus is on patients with Necrotizing Soft Tissue Infections (“flesh eating bacteria”), a rare, life threatening, infection for which no current therapy exists. AB103, the company’s lead product, is studied in ACCUTE (AB103 Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions), a phase 3 clinical trial. AB103 received Orphan Drug designation from the FDA and EMA and Fast Track designation from the FDA.
Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 in ocular melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health.
Biom’Up is a specialist in collagen-based absorbable medical devices for biosurgery and is developing a new generation hemostatic product, HEMOBLAST TM. HEMOBLASTTM Bellows is currently being tested in a prospective, randomized, controlled, multicenter, pivotal, clinical investigation evaluating the safety and efficacy in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries.
BONESUPPORT has a platform for delivering drugs to bone using CERAMENT™. This carrier is an injectable radio opaque bone void filler that rapidly remodels into bone. Bonesupport markets and sells CERAMENT™ in EU and USA and CERAMENT™ loaded with the antibiotics Gentamicin or Vancomycin in EU.
Cydan Development is an orphan drug accelerator that identifies and de-risks drug candidates targeting orphan and rare diseases and form stand-alone companies and strategic partnerships around successful such candidates.
DYSIS develops and markets next generation colposcopes for early detection and diagnosis of cervical cancer. The DYSIS colposcope is a high resolution digital colposcope with an adjunctive map. The DYSISmap is generated by a proprietary technology that measures the aceto-whitening reaction and summarizes it in the form of an intuitive map. The DYSISmap is overlaid on the live image of the cervix to help with the identification of the most relevant biopsy sites.
“Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases. Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs. Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel and gastro-intestinal diseases, Bristol-Myers Squibb in immuno-oncology. The Company was established in 2012 in Paris (France) to develop the discoveries made by the INRA metagenomic platform. Since then, the Company opened a US subsidiary in Boston and has raised a total of €53.7 million from leading venture capital investors (Seventure Partners, Lundbeckfonden Ventures, Health for Life Capital & Omnes Capital) and strategic investors (Nestlé, BMS, Shire & INRA Transfert).”
Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines. The company’s deep understanding of the role of Tissue Factor (TF) in angiogenesis, inflammation, cell growth and metastasis provides a new approach to ophthalmologic, oncologic, and autoimmune diseases. Iconic’s Phase II product candidate, ICON-1, is a novel immune-conjugate fusion protein that targets the root causes of inflammation and angiogenesis together, potentially altering the course of leading causes of blindness. Iconic’s research programs targeting the unique attributes of Tissue Factor science across multiple disease states are progressing towards IND.
Imara is developing a novel oral treatment for patients with sickle cell disease and other haemoglobinopathies.
PsiOxus Therapeutics is a development stage biotechnology company focused upon immune-oncology with headquarters near Oxford, UK and offices near Philadelphia, USA. PsiOxus has developed the proprietary Tumor-Specific Immuno-Gene therapy (T-SIGn) platform for systemic delivery of tumor-targeted oncolytic immune therapeutics. The T-SIGn platform is based on the company’s oncolytic virus, enadenotucirev, which can be delivered by intravenous administration and replicates only in tumor cells. Enadenotucirev is currently in a clinical trial under a US IND in combination with nivolumab (Opdivo ®) in collaboration with Bristol-Myers Squib (BMS). The anticancer capability of the T-SIGn platform is further enhanced through “arming” the virus with transgenes. The armed T-SIGn platform makes possible creation of a broad range of systemically delivered oncolytic immune therapeutics including oncolytic viruses that express one or more antibodies, cytokines, immunomodulatory proteins, or nucleotide (RNA) based payloads. T-SIGn thus opens up the possibility of gene therapy for cancer. NG-348, the first T-SIGn product was licensed to BMS in 2017 with an upfront payment of $50million.
Reneo has a highly experienced Orphan Diseases development team. They are developing an in-licensed, clinical stage small molecule to treat severe orphan genetic diseases that presently have no pharmaceutical treatments.
Sanifit is a biopharmaceutical company focused on the development of SNF472 – an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease (ESRD) population undergoing haemodialysis. The company has completed phase Ia studies in healthy volunteers and a phase Ib/IIa study in haemodialysis patients. Sanifit has a phase IIb Clinical Trial in ESRD called CaLIPSO ongoing and plans to extend the orphan program in calciphylaxis into phase III clinical trial.
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous, or IV, delivery. By moving delivery away from the high-cost healthcare settings typically required for IV administration, we believe our technology reduces overall healthcare costs and advances the quality and convenience of care. Our lead product candidate, Furoscix, consists of our patented subcutaneous formulation of furosemide delivered via our sc2Wear Infusor, and is under development for treatment of worsening, or decompensated, heart failure outside of the inpatient setting.
Spero is a biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The company is pioneering an entirely new therapeutic platform called the Potentiator; this approach has yielded multiple molecules that enhance the utility and potency of many classes of existing drugs to include Gram-negative pathogens. Spero’s DHFR program is exploring the expansion of a novel antifolate’s antibacterial spectrum to treat trimethoprim resistance isolates including Gram-negative pathogens.
Thesan Pharmaceuticals is a biopharmaceutical company based in San Diego, US, dedicated to the development of novel therapeutics for disorders of the skin.
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). The Company has generated clinical proof of concept data in two important itch conditions: uremic pruritus and prurigo nodularis.
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company’s unique and patented delivery technology, MeltDoseĒį, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties.
VHsquared is a clinical stage company focused on transformational oral biologics – Vorabodies™ – for inflammatory bowel disease. Vorabodies™ are oral gut-restricted domain antibodies directed at local immuno-inflammatory targets in the GI tract.